



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Pacific Edge Limited
13-Aug-25
13-Aug-25

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Anatole Masfen
Pacific Edge Limited
NA
Director

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

Ordinary shares
Beneficial owner

For that relevant interest-

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

a) Current Interest in 9,320,050 Ordinary Shares
b) Current Interest in 0 Ordinary Shares
a) Current Interest in 59,320,050 Ordinary Shares
b) Current Interest in 174,200 Ordinary Shares
a) Opito Trust
b) Apollo Holdings Limited
N/A

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

N/A
N/A

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

N/A
N/A
N/A
N/A
N/A
N/A

For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A
N/A

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

1

Details of transactions requiring disclosure-

Date of transaction:	13-Aug-25
Nature of transaction:	<p>(a) Masfen Securities, as custodian of Opito Trust purchased 50,000,000 shares during the placement component of the Capital Raise that was announced through NZX and ASX on 30 May 2025 and approved by Shareholders on 6 August 2025. Anatole Masfen is a beneficiary of Opito Trust.</p> <p>(b) Shares held by Apollo Holdings Limited were issued to Directors in recognition of the fact that shareholders have approved an increase in Director remuneration but that this increase will not be paid in cash for the period 1 April 2025 to 31 March 2026. Rather, Shares are issued to Directors in lieu of a cash payment of the amount of the increase. Anatole Masfen is a director of Apollo Holdings Limited and interests associated with Anatole Masfen hold 50% of the shares in Apollo Holdings Limited.</p> <p>This was approved by the Board on 11 July 2025 and by shareholders on 6 August 2025. Although shareholders approved the issue of up to 260,000 Shares to Anatole Masfen, the actual number of Shares (174,200) is less than this because of the "net settlement" mechanism described on page 10 of the notice of meeting released to the market on 17 July 2025.</p>
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	<p>(a) 50,000,000 Shares purchased at \$0.10 per share (\$5,000,000)</p> <p>(b) Shares issued for non cash consideration as remuneration for role as Director of the company in addition to cash-based Directors fees, with a total present value of \$17,420 (174,200 shares at \$NZD0.10 per share)</p>
Number of financial products to which the transaction related:	<p>(a) 50,000,000 Ordinary Shares</p> <p>(b) 174,200 Ordinary Shares</p>
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	
Whether relevant interests were acquired or disposed of during a closed period:	N/A
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A
Date of the prior written clearance (if any):	N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
<i>For that relevant interest,-</i>	
Number held in class:	N/A
Current registered holder(s):	N/A
<i>For a derivative relevant interest,-</i>	
Type of derivative:	N/A

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price's specified terms (if any):	N/A

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest,-</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A
N/A
N/A
N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

DocuSigned by: <i>Anatole Masfen</i> 5EE673D7F41247C...
17-Aug-2025